Last reviewed · How we verify
CT0991 CAR-T cells infusicn — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CT0991 CAR-T cells infusicn (CT0991 CAR-T cells infusicn) — MEI HENG.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CT0991 CAR-T cells infusicn TARGET | CT0991 CAR-T cells infusicn | MEI HENG | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CT0991 CAR-T cells infusicn CI watch — RSS
- CT0991 CAR-T cells infusicn CI watch — Atom
- CT0991 CAR-T cells infusicn CI watch — JSON
- CT0991 CAR-T cells infusicn alone — RSS
Cite this brief
Drug Landscape (2026). CT0991 CAR-T cells infusicn — Competitive Intelligence Brief. https://druglandscape.com/ci/ct0991-car-t-cells-infusicn. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab